| |
Newsroom /
Health and Fitness
/
Healthcare
/
Manufacturing of Biologics
Manufacturing of Biologics
The Global Biologics Industry Has Grown More Rapidly Than the Global Pharmaceutical Industry
Hyderabad,
AP,
India
(prbd.net)
01/09/2010
"Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies"
The biologics industry has emerged as a major growth area in the global healthcare industry. Since its emergence in the 1970s, the biologics industry has grown rapidly to reach approximately $128 billion in 2009. GBI Research’s analysis suggests that the biologics drugs market has outperformed the pharmaceutical market in the past few years. The biologics industry had a year on year average growth rate of approximately 11.5% over the period of 2007–2009. This is significantly higher than the pharmaceutical industry’s growth rate of 6% in the same time period. It is expected to grow by 9.3% for the period of 2009–2016.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Manufacturing-of-Biologics-Increasing-Demand-for-Monoclonal-Antibodies-and-Recombinant-Proteins-Drives-Increases-in-Capacities-and-Innovative-Production-Technologies&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
The use of CMOs is one of the most significant trends in the healthcare industry, especially in the biologics market. CMOs will be used for most of the processes in the industry. Although the CMO market is not growing much at the moment due to capacity expansions by major companies such as Lonza Group Ltd., Boehringer Ingelheim (BI), and many more. Their focus has been shifted towards setting up new plants, buying new equipments. These expansion processes indicate the future prospects of the industry. Many experts in the industry have already predicted that the future of the CMO market is bright. Several players from emerging countries are entering the market. Companies are opening up beginning operations in emerging countries such as India, China, and Singapore.
GBI Research suggests that the CMO biologics market is set to grow at a CAGR of 13.4%, (2009-16) which is faster than the overall CMO market. The market shares of CMOs the developed countries are expected to decline in the coming years due to the high cost of operations and due to the development taking place in the emerging markets. The share of the emerging markets is expected to more than double by 2013 and to triple by 2016.
GBI Research's report, “Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies”, provides the key data and analyzes the major challenges and drivers for the bio-manufacturing industry. The report also analyzes the strengths, weaknesses of and opportunities for the stakeholders in the manufacturing of biologics. The report also discusses the key market drivers and barriers for the growth of bio-manufacturing in the pharmaceutical and biotech industry. The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts to provide a comprehensive view of the manufacturing of biologics.
For further details, please click or add the below link to your browser:
http://www.gbiresearch.com/Report.aspx?ID=Manufacturing-of-Biologics-Increasing-Demand-for-Monoclonal-Antibodies-and-Recombinant-Proteins-Drives-Increases-in-Capacities-and-Innovative-Production-Technologies&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|